ChemicalBook CAS DataBase List 30010-41-4

30010-41-4

Name	erythromycin aspartate
CAS	30010-41-4
Molecular Formula	C37H67NO13.C4H7NO4
MDL Number	MFCD01744427
Molecular Weight	867.033
MOL File	30010-41-4.mol

Hazard Information

Uses

Erythromycin aspartate is a macrolide antibiotic produced by actinomycete?Streptomyces erythreus?with a broad spectrum of antimicrobial activity. Erythromycin aspartate binds to bacterial 50S ribosomal subunits and inhibits?RNA-dependent protein synthesis?by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid[1][2]. Erythromycin aspartate also exhibits antitumor and neuroprotective effect in different fields of research[3][4].

in vivo

Erythromycin aspartate (gastric intubation; 0.1-50 mg/kg; 30-120 days) decreases tumor growth and prolong the survival time of mice from dose of 5 mg/kg in mice^[3].
Erythromycin aspartate (gastric intubation; 5 mg/kg) protects mice alive even at 120 days after inoculation, but shortens mean survival time in tumor-bearing mice by 4-5 days with dose of 50 mg/kg^[3].
Erythromycin aspartate (i.h.; single injection; 50 mg/kg) has a protective effect on the rat model with cerebral ischemia reperfusion-injury^[4].

Animal Model:	Female ddY mice (6-week-old) with EAC cells or CDF mice (6-week-old) with P388 cells^[3]
Dosage:	0.1 mg/kg; 0.5 mg/kg; 10 mg/kg; 30 mg/kg; 50 mg/kg
Administration:	Gastric intubation; 30-120 days
Result:	Decreased tumor growth and prolonged the mean survival time of mice from the dose of 5 mg/kg, however, the 50 mg/kg dosage shortened the MST in tumorbearing mice.

Animal Model:	Male Sprague-Dawley rats (8-week-old, 250-300 g)^[4]
Dosage:	50 mg/kg
Administration:	Subcutaneous single injection
Result:	Reduced infarct volume and edema volume, improved neurological deficit.

IC 50

Macrolide

References

[1] Gribble MJ, et al. Erythromycin. Med Clin North Am. 1982 Jan;66(1):79-89. DOI:10.1016/s0025-7125(16)31443-2
[2] Nakornchai S, et al. Activity of azithromycin or erythromycin in combination with antimalarial drugs against multidrug-resistant Plasmodium falciparum in vitro. Acta Trop. 2006 Dec. 100(3):185-91. DOI:10.1016/j.actatropica.2006.10.008
[3] Hamada K, et al. Antitumor effect of erythromycin in mice. Chemotherapy. 1995 Jan-Feb. 41(1):59-69. DOI:10.1159/000239325
[4] Katayama Y, et al. Neuroprotective effects of erythromycin on cerebral ischemia reperfusion-injury and cell viability after oxygen-glucose deprivation in cultured neuronal cells. Brain Res. 2014 Nov 7. 1588:159-67. DOI:10.1016/j.brainres.2014.09.016

Send Inquriy